Compare Nutrien Ltd (NTR) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Nuwellis Inc — how do they compare? Nutrien Ltd trades at $69.9 (market cap $33.31B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Nutrien Ltd is far larger — about 15140.9× Nuwellis Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Nuwellis Inc for 26 Days on average.
| NTR | NUWE | |
|---|---|---|
Market Cap | $33.31B | $2.20M |
Volume | 1,330,729 | 121,544 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $146.65 |
52-Week Low | $53.64 | $0.68 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $45.11B | -$1.52M |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.97, down 1.73% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with revenue stabilizing around $26-28B and net margins improving to 8.44%. Recent news highlights industry headwinds from potential Belarus potash imports, though strong fertilizer prices and cost discipline support cash flow. Analyst consensus remains moderately bullish with a $76.14 price target, representing 9% upside potential from current levels.
Investment outlook balances cyclical fertilizer demand against structural advantages. Near-term risks include competitive pressure from potential Belarus imports and sulfur cost inflation, but North American gas arbitrage and agricultural cycle recovery provide catalysts. With reasonable valuation (P/E 14.16) and 60% analyst buy ratings, the stock offers value for patient investors despite technical weakness.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
